Novartis is advancing studies with its experimental asthma therapy fevipiprant in India, amid significant expectations around its possible impact on market dynamics including aspects such as the potentially shared patient pool with certain biologics.

In another vote of confidence in one of its newer respiratory assets, AstraZeneca is extending to Asia its already broad rights to benralizumab, adding to a deal it already has with Kyowa Hakko Kirin for Japan.